Table 1.
Characteristics of Participants in the COGENT Study After Adaptation for MGP by Type of Testing Offered
| Characteristic | Offered Targeted Testing Only (n= 205) |
Offered Multigene Panel Testing (n = 395) |
P |
|---|---|---|---|
| Had MGP testing, No. (%) | |||
| Yes | NA | 376 (95) | |
| No | NA | 19 (5) | |
| Mean age, years (range) | 46 (21–86) | 51 (19–82) | < .001 |
| SD | 14.0 | 11.7 | |
| Sex, No. (%) | < .001 | ||
| Female | 181 (88) | 387 (98) | |
| Male | 24 (12) | 8 (2) | |
| Race, No. (%) | NSS | ||
| White | 170 (83) | 319 (81) | |
| Nonwhite | 35 (17) | 76 (19) | |
| Education, No. (%) | NSS | ||
| Some college or less | 69 (34) | 156 (39) | |
| College degree or more | 135 (65) | 238 (60) | |
| Refused to answer | 1 (< 1) | 1 (< 1) | |
| Ashkenazi Jewish, No. (%) | .001 | ||
| Yes | 55 (27) | 27 (7) | |
| No | 144 (70) | 366 (93) | |
| Not captured | 6 (3) | 2 (< 1) | |
| Personal history of cancer, No. (%) | ≤ .001 | ||
| Yes | 81 (40) | 270 (68) | |
| No | 124 (60) | 125 (32) | |
| Mean No. of FDRs and SDRs (SD) | 3.63 (2.11) | 3.83 (2.40) | NSS |
| Known mutation, No. (%) | < .001 | ||
| Yes | 102 (50) | 16 (4) | |
| No | 103 (50) | 379 (96) | |
| Testing for surgical treatment decision, No. (%) | NSS | ||
| Yes | 11 (5) | 10 (3) | |
| No | 194 (95) | 385 (97) | |
| Randomly assigned, No. (%) | ≤ .001 | ||
| Yes | 187 (91) | 309 (78) | |
| No | 18 (9) | 86 (22) | |
| Study site, No. (%) | ≤ .001 | ||
| 1 | 74 (36) | 75 (19) | |
| 2 | 47 (23) | 196 (50) | |
| 3 | 60 (29) | 75 (19) | |
| 4 | 6 (3) | 12 (3) | |
| 5 | 18 (9) | 37 (9) | |
| Result of testing, No. (%)* | ≤ .001 | ||
| Positive | 46 (26) | 23 (8) | |
| Variant of undetermined significance | 3 (2) | 77 (25) | |
| Negative | 81 (47) | 203 (66) | |
| True negative | 44 (25) | 3 (1) |
Abbreviations: COGENT, Communication of Genetic Test Results by Telephone; FDR, first-degree relative; MGP, multigene panel; NA, not applicable; NSS, not statistically significant; SD, standard deviation; SDR, second-degree relative.
*
Thirty-one patients in the targeted testing group and 89 patients in multigene panel testing group were excluded because testing was cancelled or the patient withdrew pre-disclosure.